Rui Wang

Rui Wang

Auto-generated profile, based on publicly available information

Rui Wang

Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2018 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YYYan Yang
Yan Yang
JZJian Zhu
Jian Zhu
TZTiantian Zhang
Tiantian Zhang
JLJing Liu
Jing Liu
YLYumei Li
Yumei Li
QWQiong Wu
Qiong Wu
Background: PHD-finger domain protein 5A (PHF5A) is a highly conserved small transcriptional regulator also involved in pre-mRNA splicing; however, its biological functions and molecular mechanisms in non-small cell lung cancer (NSCLC) have not yet been investigated. The purpose of this study was to determine the functional relevance and therapeutic potential of PHF5A in lung adenocarcinoma (LAC). Methods: The expression of PHF5A in LAC tissues and adjacent non-tumor (ANT) tissues was investigated using immunohistochemistry of a tissue microarray, qRT-PCR, western blot and bioinformatics. The function of PHF5A was determined using several in vitro assays and also in vivo assay by lentiviral vector-mediated PHF5A depletion in LAC cell lines. Results: PHF5A was highly upregulated in LAC tissues compared with the ANT counterparts, and closely associated with tumor progression and poor patient prognosis. These results were further confirmed by findings of the TCGA database. Moreover, functional studies demonstrated that PHF5A knockdown not only resulted in reduced cell proliferation, increased cell apoptosis, and cell cycle arrest, but also suppressed migration and invasion in LAC cells. PHF5A silencing was also found to inhibit LAC tumor growth in nude mice. Microarray and bioinformatics analyses revealed that PHF5A depletion led to dysregulation of multiple tumor signaling pathways; selected factors in key signaling pathways were verified in vitro. Conclusions: The data suggest for the first time that PHF5A is an oncoprotein that contributes to LAC progression by regulating multiple signaling pathways, and may constitute a prognostic factor and potential new therapeutic target in NSCLC.

9 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TZTiantian Zhang
Tiantian Zhang
YZYangyang Zhou
Yangyang Zhou
YWYue Wu
Yue Wu
MSMengting Shi
Mengting Shi
WSWeijie Sun
Weijie Sun
RWRui Wang
Rui Wang
Patients with advanced pancreatic ductal adenocarcinoma (PDAC) generally face a poor prognosis and limited therapeutic options. This study aims to evaluate the clinical efficacy of combining PD- 1 inhibitors with chemotherapy as a first-line treatment for advanced PDAC, and to explore the correlation between various clinical parameters and treatment outcomes.This retrospective study analyzed the clinical data of 57 patients with advanced PDAC treated at the First Affiliated Hospital of Bengbu Medical University from January 2022 and June 2024. Patients were allocate into the two groups: the chemotherapy-alone group (29 cases) (CT), which received either the AG regimen or the mFOLFIRINOX regimen, and the imimmunotherapy plus chemotherapy group (28 cases) (ICT), which received the AG regimen or mFOLFIRINOX regimen in combination with PD- 1 inhibitors.The study compared progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse reactions between the two groups. Additionally, it analyzed the correlation between various clinical indicators and their dynamic changes over time in relation to treatment outcomes. Kaplan-Meier curves were plotted for survival analysis, and log-rank tests assessed PFS and OS differences.Univariate and multivariate Cox regression analyses identified independent risk factors for prognosis, while logistic regression assessed the correlation between these factors and treatment response.The median PFS and OS in immunotherapy plus chemotherapy group were significantly superior to those in the chemotherapy-alone group (PFS: 7.3 vs. 5.8 months, P = 0.005; OS: 12 vs. 10.2 months, P = 0.031). The ORR in the group receive immunotherapy combined with chemotherapy was also significantly higher compared to the group treated with chemotherapy alone (42.86% vs. 17.24%, P = 0.03). No significant differences were observed in the incidence or severity of treatment-related adverse events (TRAEs) and immunotherapy-related adverse events (irAEs) between the CT and ICTgroups (any grade: 93.10% vs. 96.45%, P = 0.574; grade 3 or 4: 31.3% vs. 28.57%, P = 0.839). Patients without liver metastasis, without diabetes, or those who experience a increase in SOD levels following treatment may constitute an advantageous population for immune combination therapy. In conclusion, chemotherapy combined with PD- 1 inhibitors demonstrated favorable safety and tolerability, and significantly improved PFS, OS, and ORR compared to chemotherapy alone.

18 April 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
TZTiantian Zhang
Tiantian Zhang
SHShuo He
Shuo He
LTLu Tao
Lu Tao
MSMengting Shi
Mengting Shi
YWYue Wu
Yue Wu
RWRui Wang
Rui Wang
Objective This study aims to assess the efficacy and safety of RC48 in combination with PD-1 inhibitors for patients diagnosed with locally advanced or metastatic urothelial carcinoma (mUC). Methods A retrospective analysis was performed on clinical data from 53 patients with locally advanced or metastatic bladder cancer, who were treated at the First Affiliated Hospital of Bengbu Medical College between January 2023 and December 2023. The cohort was stratified into two groups: the RC48 combined immunotherapy group (RC48 + PD-1, n = 27) and the conventional chemotherapy group (gemcitabine and cisplatin regimen, GP, n = 26). Results The RC48 + PD-1 group demonstrated significantly higher objective response rates (ORR) and median progression-free survival (PFS) compared to the chemotherapy group (P < 0.05). Notably, the incidence of grade 3 or higher adverse events was elevated in the chemotherapy cohort, predominantly due to hematologic toxicities, with no treatment-related fatalities reported. In contrast, the RC48 combined PD-1 group primarily experienced immune-related adverse events, without any incidents of grade 3 or higher adverse effects or treatment-related deaths. Conclusion The combination of RC48 and PD-1 inhibitors exhibits promising antitumor activity and a manageable safety profile in patients with locally advanced or metastatic UC.

1 April 2016 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
JHJian-Guo Hu
Jian-Guo Hu
QQQi Qi
Qi Qi
YZYuxin Zhang
Yuxin Zhang
LSLin Shen
Lin Shen
RWRui Wang
Rui Wang
JZJiansheng Zhou
Jiansheng Zhou
Purpose: Our purpose was to systematically investigate the expression pattern and role of Olig1 in neural cells during rat spinal cord development. Animals and methods: Spinal cord tissues were dissected from Sprague–Dawley rats at embryonic day 14.5 (E14.5) and E18.5, postnatal day 0 (P0), P3, P7, postnatal 2 weeks (P2W), P4W, and adults (more than 2 months after birth), respectively. The expression of Olig1 was determined by Western blot and immunostaining. To observe expression of Olig1 in different neural cell types, a double immunohistochemical staining was performed using antibodies against Olig1 with O4, ß-tubulin, glial fibrillary acidic protein (GFAP), and myelin basic protein, respectively. Results: The expression of Olig1 protein shows a significant level change in rat spinal cord at different developmental time points. Starting with E14.5, the expression gradually increased and peaked at E18.5. Olig1 decreased gradually from P3 and reached its lowest level on P7. However, interestingly, the Olig1 expression increased again from P2W, until adulthood. Olig1 was coexpressed with O4-positive oligodendrocyte progenitor cells (OPCs) and β-tubulin-positive neurons at all time points during development. Olig1 was also coexpressed transiently with GFAP-positive astrocytes at only E14.5. Olig1 was localized in the cytoplasm of O4- and β-tubulin-positive cells during the period from E14.5 to adult. Conclusion: The expression of Olig1 in OPCs and neurons at all time points during development and in astrocytes at E14.5 suggests that Olig1 may play an important role in the generation and maturation of specific neural cells during development of spinal cord. Our results contribute to understanding the mechanism underlying developmental regulation of neural cells by Olig1.

8 August 2024 in The Clinical Respiratory Journal
Verified
Journal Article
Open access
TZTiantian Zhang
Tiantian Zhang
LTLu Tao
Lu Tao
YCYufo Chen
Yufo Chen
SZShanshan Zhang
Shanshan Zhang
YLYang Liu
Yang Liu
RWRui Wang
Rui Wang
Background: Small cell lung cancer (SCLC) is a highly aggressive tumor with limited effectiveness in its standard chemotherapy treatment. Targeted antiangiogenic therapy and immune checkpoint inhibitors (ICIs) have demonstrated potential as alternative treatments for extensive‐stage SCLC (ES‐SCLC). However, there is insufficient comparative evidence available to determine the optimal first‐line treatment option between ICIs plus chemotherapy and targeted antiangiogenic therapy plus chemotherapy.Objective: This study is aimed at analyzing clinical data from ES‐SCLC patients treated at the First Affiliated Hospital of Bengbu Medical College between June 2021 and June 2023. The study compared the efficacy and safety of three first‐line treatment regimens: standard chemotherapy, antiangiogenic therapy combined with chemotherapy, and immune combination therapy.Methods: Patients who met the inclusion criteria were divided into three groups: chemotherapy, immune combination therapy, and antiangiogenic therapy combined with chemotherapy. The study collected data on clinical characteristics, treatment regimens, and adverse reactions. The analysis included objective response rate (ORR), duration of response (DoR), disease control rate (DCR), progression‐free survival (PFS), and treatment safety.Results: A total of 101 patients were included in the study, with 49 receiving chemotherapy alone, 19 receiving antiangiogenic therapy, and 33 receiving immune combination therapy. The ORRs were 78.9% for antiangiogenic therapy, 72.7% for immune combination therapy, and 42.9% for chemotherapy alone. The median PFS was 8.0 months for antiangiogenic therapy, 7.8 months for immune combination therapy, and 5.2 months for chemotherapy alone. Both combination therapy groups demonstrated superior efficacy compared to chemotherapy alone.Conclusion: Targeted combined chemotherapy and immune combination chemotherapy showed superior efficacy as first‐line treatments for ES‐SCLC compared to chemotherapy alone, with manageable adverse reactions.

15 March 2025 in iScience
Verified
Journal Article
Open access
FXFang Xue
Fang Xue
JLJing Liu
Jing Liu
JWJinyan Wu
Jinyan Wu
XLXueer Li
Xueer Li
NZNingning Zhu
Ningning Zhu
JZJing Zhang
Jing Zhang
Alisertib is a potent aurora A kinase inhibitor in clinical trials for cancer treatment, but its efficacy on cancer vaccines remains unclear. Here, we developed a DNA vaccine targeting glypican-3 (pGPC3) and evaluated its efficacy with alisertib in hepatocellular carcinoma (HCC) models. The combination therapy of pGPC3 vaccine and alisertib significantly inhibited subcutaneous tumor growth, enhanced the induction and maturation of CD11c+ and CD8+CD11c+ dendritic cells (DCs), and expanded tumor-specific CD8+ T cell responses. CD8+ T cell depletion abolished the anti-tumor effects, underscoring the essential role of functional CD8+ T cell responses. Moreover, the combined treatment promoted memory CD8+ T cell induction, providing long-term protection. In liver orthotopic tumor models, the combination of pGPC3 vaccine and alisertib demonstrated potent therapeutic efficacy through CD8+ T cell responses. These results indicate that alisertib enhances the pGPC3 vaccine's therapeutic effect, offering a promising strategy for HCC treatment.